Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Evolus, Inc. has received an average rating of "Moderate Buy" from five research firms, with one hold and four buy recommendations.
• The average 1-year price objective for Evolus stock among analysts is $21.25, although recent ratings have seen price objectives adjusted downward.
• Insider transactions showed a significant purchase by Director Albert G. White III, who acquired 20,000 shares, indicating confidence in the company's prospects.

Shares of Evolus, Inc. (NASDAQ:EOLS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $21.25.

A number of brokerages have recently issued reports on EOLS. Wall Street Zen downgraded shares of Evolus from a "hold" rating to a "sell" rating in a research report on Saturday. HC Wainwright cut their price objective on shares of Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Needham & Company LLC reaffirmed a "hold" rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, August 6th. Finally, BTIG Research cut their price objective on shares of Evolus from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th.

Insider Buying and Selling

In other Evolus news, Director Albert G. White III purchased 20,000 shares of the stock in a transaction on Monday, June 9th. The shares were bought at an average price of $9.45 per share, for a total transaction of $189,000.00. Following the completion of the transaction, the director owned 50,378 shares of the company's stock, valued at $476,072.10. This trade represents a 65.84% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider David Moatazedi sold 111,323 shares of the stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $10.05, for a total value of $1,118,796.15. Following the transaction, the insider owned 381,509 shares in the company, valued at $3,834,165.45. This trade represents a 22.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in EOLS. KLP Kapitalforvaltning AS purchased a new position in shares of Evolus during the 4th quarter valued at approximately $106,000. Geode Capital Management LLC increased its stake in Evolus by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company's stock worth $13,412,000 after buying an additional 3,969 shares in the last quarter. ExodusPoint Capital Management LP purchased a new stake in Evolus during the 4th quarter worth approximately $149,000. Wells Fargo & Company MN increased its stake in Evolus by 41.6% during the 4th quarter. Wells Fargo & Company MN now owns 49,347 shares of the company's stock worth $545,000 after buying an additional 14,506 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd increased its stake in Evolus by 60.3% during the 4th quarter. Dynamic Technology Lab Private Ltd now owns 18,886 shares of the company's stock worth $208,000 after buying an additional 7,103 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company's stock.

Evolus Stock Up 2.1%

Shares of EOLS traded up $0.14 during mid-day trading on Friday, hitting $6.54. The company's stock had a trading volume of 578,722 shares, compared to its average volume of 1,098,312. The company's 50-day moving average is $9.09 and its 200-day moving average is $11.01. Evolus has a 52-week low of $5.71 and a 52-week high of $17.82. The firm has a market capitalization of $422.85 million, a price-to-earnings ratio of -6.63 and a beta of 1.12. The company has a current ratio of 2.27, a quick ratio of 1.86 and a debt-to-equity ratio of 22.00.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.